These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1147 related articles for article (PubMed ID: 27697899)

  • 21. Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.
    Neggers SJ; Pronin V; Balcere I; Lee MK; Rozhinskaya L; Bronstein MD; Gadelha MR; Maisonobe P; Sert C; van der Lely AJ;
    Eur J Endocrinol; 2015 Sep; 173(3):313-23. PubMed ID: 26047625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M; Strosberg J
    Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
    Colao A; Bronstein MD; Freda P; Gu F; Shen CC; Gadelha M; Fleseriu M; van der Lely AJ; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Sheppard M;
    J Clin Endocrinol Metab; 2014 Mar; 99(3):791-9. PubMed ID: 24423324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.
    Feelders RA; Hofland LJ; van Aken MO; Neggers SJ; Lamberts SW; de Herder WW; van der Lely AJ
    Drugs; 2009 Nov; 69(16):2207-26. PubMed ID: 19852525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastroenteropancreatic neuroendocrine tumors: hormonal treatment updates.
    Khagi S; Saif MW
    JOP; 2014 Mar; 15(2):135-7. PubMed ID: 24618437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The future of somatostatin analogue therapy.
    Stewart PM; James RA
    Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Oct; 13(3):409-18. PubMed ID: 10909432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    McKeage K; Cheer S; Wagstaff AJ
    Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatostatin Analogs in Clinical Practice: a Review.
    Gomes-Porras M; Cárdenas-Salas J; Álvarez-Escolá C
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
    Arnold R; Simon B; Wied M
    Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
    Oberg K
    Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
    Samson SL
    Neuroendocrinology; 2015; 102(1-2):8-17. PubMed ID: 25792118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety of lanreotide for neuroendocrine tumor.
    Godara A; Siddiqui NS; Byrne MM; Saif MW
    Expert Opin Drug Saf; 2019 Jan; 18(1):1-10. PubMed ID: 30582380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pasireotide in Acromegaly: A Review.
    McKeage K
    Drugs; 2015 Jun; 75(9):1039-48. PubMed ID: 26017304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
    Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
    Murray RD; Melmed S
    J Clin Endocrinol Metab; 2008 Aug; 93(8):2957-68. PubMed ID: 18477663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
    Suda K; Inoshita N; Iguchi G; Fukuoka H; Takahashi M; Nishizawa H; Yamamoto M; Yamada S; Takahashi Y
    Endocr J; 2013; 60(4):507-15. PubMed ID: 23291436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
    Modlin IM; Pavel M; Kidd M; Gustafsson BI
    Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.